CN104906418A - Medicine composition with anti-allergic effect - Google Patents
Medicine composition with anti-allergic effect Download PDFInfo
- Publication number
- CN104906418A CN104906418A CN201510324620.5A CN201510324620A CN104906418A CN 104906418 A CN104906418 A CN 104906418A CN 201510324620 A CN201510324620 A CN 201510324620A CN 104906418 A CN104906418 A CN 104906418A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- allergic
- compositions
- flos chrysanthemi
- tremella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title claims abstract description 21
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 21
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 18
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 18
- 208000006673 asthma Diseases 0.000 claims abstract description 18
- 241001506047 Tremella Species 0.000 claims abstract description 17
- 244000269722 Thea sinensis Species 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 239000006187 pill Substances 0.000 claims abstract description 8
- 201000009961 allergic asthma Diseases 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 20
- 244000183685 Citrus aurantium Species 0.000 claims description 16
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 16
- 235000003935 Hippophae Nutrition 0.000 claims description 16
- 241000229143 Hippophae Species 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 206010050639 Allergic pharyngitis Diseases 0.000 claims description 6
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 6
- 235000013616 tea Nutrition 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 235000009569 green tea Nutrition 0.000 claims description 4
- 230000002804 anti-anaphylactic effect Effects 0.000 claims description 2
- 240000005385 Jasminum sambac Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 8
- 208000026935 allergic disease Diseases 0.000 abstract description 8
- 230000000172 allergic effect Effects 0.000 abstract description 7
- 230000007815 allergy Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 208000010668 atopic eczema Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 3
- 238000003915 air pollution Methods 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 244000144725 Amygdalus communis Species 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 235000020224 almond Nutrition 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 15
- 201000007100 Pharyngitis Diseases 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 206010002198 Anaphylactic reaction Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 230000036783 anaphylactic response Effects 0.000 description 6
- 208000003455 anaphylaxis Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003800 pharynx Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000207840 Jasminum Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000002052 anaphylactic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000016150 acute pharyngitis Diseases 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940088529 claritin Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine composition with an anti-allergic effect. The composition is composed of tremella, platycodon grandiflorum, rhizoma phragmitis, almonds, sea-buckthorn, orange blossom, chrysanthemum and tea leaves. A preparation method for the composition disclosed by the invention comprises the following steps: cleaning and airing raw material medicines respectively, grinding the raw material medicines into fine powders, uniformly mixing all the raw material medicine fine powders, then adding conventional auxiliary materials according to a conventional process to prepare clinically acceptable tea bags, capsules, tablets, pills, granules or oral solution. The medicine composition disclosed by the invention has the effects of moistening lung, resisting inflammation, dredging orifices and resisting allergy, is especially remarkable in effects on allergic acute and chronic aryngitis, allergic rhinitis and allergic asthma caused by air pollution and serious hazy weather, and free from side effects.
Description
Technical field
The present invention relates to a kind of compositions, particularly relate to a kind of pharmaceutical composition with anti-allergic effects.
Background technology
Anaphylaxis, also known as allergy (allergy), is the tissue injury or physiological dysfunction that cause after body is stimulated by antigenicity substance, belongs to abnormal, pathologic immunoreation.Allergic rhinitis, asthma, pruritus etc. are all comparatively common anaphylaxis.Along with the continuous deterioration of global ecological environment, the generation of hypersensitivity disorders constantly increases.Domestic Epidemiological study display, the sickness rate of current China allergic disease is up to 37.5%.Allergic disease has badly influenced life and the life of the mankind, becomes global great public health problem, is classified as 21 century primary study and one of the three large diseases of control by World Health Organization (WHO) (WHO).
At present, air pollution is serious, often occurs haze weather, is the high-incidence season of suffering from anaphylaxis respiratory disorder and allergic rhinitis.Western medical treatment anaphylactic disease many employings antihistaminic, hormones and receptor antagonist etc.Drug effect is fast, symptomatic treatment successful.As antihistamine drug, structurally similar to histamine, its effect to peripheral tissues is blocked by competition histamine receptor.But still there is very large defect in treatment, often action time is short, easily recur after drug withdrawal, particularly can cause the even side effect such as induced cardiotoxicity of CNS inhibition, cholinolytic effect, as conventional chlorphenamine, diphenhydramine, promethazine, Cyproheptadine etc., with rear have drowsiness, the side effect such as xerostomia, dizziness, patient does not take like a shot, and high-altitude, high-speed job person can not use during operation, easily produce drug resistance again when life-time service.Therefore, research and searching high-efficiency low-toxicity, effective Claritin are still an important and urgent global task.The research of Traditional Chinese Medicine Anti allergy has had certain history; the effect of Chinese medicine in antianaphylaxis too many levels often; as suppress the generation of IgE, protection and stable target cell membrane (reduce and prevent its retting conditions, release Anaphylactic mediator), antagonism Anaphylactic mediator, in and allergen etc.; and Traditional Chinese Medicine Anti allergy does not have the side effect such as the CNS inhibition of existing Western medicine, has the advantage that Western medicine does not possess.From Chinese medicine, develop better Claritin there is very large meaning.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition with anti-allergic effects.
The present invention is achieved through the following technical solutions:
The crude drug of the present composition consists of:
Tremella 2-10 weight portion Radix Platycodonis 0.5-2.5 weight portion Rhizoma Phragmitis 0.5-4 weight portion
Semen Armeniacae Amarum 0.5-4 weight portion Fructus Hippophae 0.1-1 weight portion Citrus aurantium L. var. amara Engl. 0.05-0.4 weight portion
Flos Chrysanthemi 0.3-2 weight portion Folium Camelliae sinensis 5-25 weight portion.
The crude drug of the present composition consists of:
Tremella 3-7 weight portion Radix Platycodonis 1-2 weight portion Rhizoma Phragmitis 1-3 weight portion
Semen Armeniacae Amarum 1-3 weight portion Fructus Hippophae 0.3-0.7 weight portion Citrus aurantium L. var. amara Engl. 0.1-0.3 weight portion
Flos Chrysanthemi 0.5-1.5 weight portion Folium Camelliae sinensis 10-16 weight portion.
The crude drug composition of the present composition is preferably:
Tremella 5 weight portion Radix Platycodonis 1.5 weight portion Rhizoma Phragmitis 2 weight portion
Semen Armeniacae Amarum 2 weight portion Fructus Hippophae 0.5 weight portion Citrus aurantium L. var. amara Engl. 0.2 weight portion
Flos Chrysanthemi 1 weight portion Folium Camelliae sinensis 13 weight portion.
The crude drug composition of the present composition is preferably:
Tremella 3 weight portion Radix Platycodonis 2.3 weight portion Rhizoma Phragmitis 1 weight portion
Semen Armeniacae Amarum 3 weight portion Fructus Hippophae 0.2 weight portion Citrus aurantium L. var. amara Engl. 0.3 weight portion
Flos Chrysanthemi 0.5 weight portion Folium Camelliae sinensis 20 weight portion.
The crude drug composition of the present composition is preferably:
Tremella 9 weight portion Radix Platycodonis 0.7 weight portion Rhizoma Phragmitis 3.8 weight portion
Semen Armeniacae Amarum 1 weight portion Fructus Hippophae 0.8 weight portion Citrus aurantium L. var. amara Engl. 0.1 weight portion
Flos Chrysanthemi 1.8 weight portion Folium Camelliae sinensis 8 weight portion.
Semen Armeniacae Amarum described in the present composition is Semen Armeniacae Amarum or Semen pruni armeniacae; Described Flos Chrysanthemi is Flos Chrysanthemi; Described Folium Camelliae sinensis is green tea or Jasmine tea.
The present composition is teabag, capsule, tablet, pill, granule or oral liquid.
The preparation method of the present composition is: above-mentioned raw materials medicine is cleaned respectively, dried, wears into fine powder, by all crude drug fine powder mix homogeneously.Described fine powder was the powder of 80 mesh sieves.
The preparation method of the invention described above compositions can conveniently technique add customary adjuvant and makes the teabag of clinical acceptance, capsule, tablet, pill, granule or oral liquid.
Pharmaceutical composition of the present invention has lung moistening, anti-pharynx, sensible and antianaphylactic effect, and be especially air pollution, the anaphylaxis acute/chronic pharyngitis that haze weather seriously causes, allergic rhinitis, allergic asthma Be very effective, have no side effect.
Experimental example is used for further illustrating the present invention below, but is not limited to the present invention.
Experimental example one: animal pharmacodynamics test
Antiallergic effect is studied: test proves, the present composition (hereinafter referred to as reagent of the present invention, according to the preparation of embodiment 1 method) antiallergic effective ingredient, has good antiallergic effect.Experimental technique and result as follows:
One, materials and methods
1. sample preparation
Get reagent 1g of the present invention, adding distil water is mixed with the solution of 1mg/mL (low dose group), 10mg/mL (middle dosage group), 50mg/mL (high dose group) respectively.
2. laboratory animal
Kunming mice, 72, male and female half and half, body weight (22 ± 2) g.
Two, test method
Get healthy Kunming mouse body weight 20g-24g, be divided into reagent of the present invention high, medium and low dosage group, positive group, model group and blank group at random, often organize 12.With 8% sodium sulfide alcoholic solution at back depilation (2cm × 3cm), to be coated on depilation district skin by reagent, once a day, successive administration 7 days, positive group, model group and positive group are coated with inequality distilled water, in subcutaneous injection 4-AP (normal saline is made into 0.02%) the solution 0.01mL/g at coating position, nape portion after last administration 40min, blank group injecting normal saline, record each group and lick body number of times (lick body continuously to there is minibreak, do lick body once calculate) in 10min.
Three, result
Reagent antiallergic effective ingredient of the present invention is on the impact of 4-AP sensitized mice pruritus model Licking response number of times
Model group compares with blank group, licks body number of times showed increased, and difference has significant (P<0.01); The high, medium and low dosage group of reagent antiallergic effective ingredient of the present invention all obviously can reduce the Licking response number of times of the skin pruritus model of 4-AP induction, and compare with model control group, difference all has significant (P<0.01); High dose group and positive controls comparing difference do not have significant (P>0.05).
| Group | Quantity (n) | Body number of times is licked in 10min |
| High dose group | 12 | 21±4 |
| Middle dosage group | 12 | 18±5 |
| Low dose group | 12 | 15±3 |
| Positive group | 12 | 28±4 |
| Model group | 12 | 50±5 |
| Blank group | 12 | 32±4 |
Four, conclusion
Reagent effective ingredient of the present invention has good antiallergic effect.
Experimental example two, clinical trial
1, clinical observation
Teabag of the present invention (according to the preparation of embodiment 1 method) is to each 100 examples for the treatment of allergic pharyngitis, allergic rhinitis and isolated from allergic asthmatic patients, and wherein male 50 example, women 50 is routine.
2, medicament selection
Treatment group anthology invention teabag (according to the preparation of embodiment 1 method), two courses for the treatment of (5 days courses for the treatment of), 2g/ bag, once-a-day, each 1 bag, boiled water brews.
3, diagnostic criteria
(1) allergic rhinitis
One of diagnostic criteria of allergic rhinitis, allergic rhinitis cardinal symptom are as rhinocnesmus, continuously sneeze, a large amount of clear water sample nasal mucus etc.
The diagnostic criteria two of allergic rhinitis, anterior rhinoscopy: the visible pale edema of nasal mucosa, if can there is nasal polyp or polypoid degeneration because of persistency edema in a large amount of clear watery secretion.
The diagnostic criteria three of allergic rhinitis, there is typical hypersensitive medical history (comprise anaphylactic disease family history, I infant eczema or asthma medical history) and typical clinical symptoms.
The diagnostic criteria four of allergic rhinitis, allergic effect source tuerculoderma: the speed after main detection skin test sends out phase anaphylaxis are the Main Diagnosis methods in current allergy educational circles, and it has been widely used in the anaphylaxis detecting IgE mediation.Allergic effect source tuerculoderma once can provide the result of the test in multiple allergic effect source at short notice simultaneously, simple and convenient.It should be noted that the operational approach due to skin test and the evaluation methodology to result are comparatively complicated, therefore should be implemented by the medical worker through specialized training.
The diagnostic criteria five of allergic rhinitis, nasal secretion plate coating checking: between allergy stage of attack, in nasal discharge, visible hypereosinophilic, also can look into and see more eosinophil leucocyte or mastocyte.
(2) allergic pharyngitis
1) have acute pharyngitis or chronic pharyngitis to bring out medical history, the course of disease is the several months or year in year out, the four seasons are visible, based on winter-spring season morbidity.
2) paroxysmal zest itching throat and dry cough, continues several tens of seconds or several minutes, a burst of outbreak at every turn, obvious with day or night.General without obvious pharyngalgia, can with dry pharynx sense of discomfort.
3) check: pharyngeal inspection without obvious pathological changes, or can have the acute, chronic pharyngitis signs such as the slight micro-hyperemia of pharynx mucosa, plumpness, but is not true to type more.
4) allergen skin test is positive result more.
(3), allergic asthma
All there is allergic phenomena or have allergic rhinitis in major part isolated from allergic asthmatic patients, omen has sneeze, rhinorrhea, rhinocnesmus, ophthalmic pruritus, the symptom such as to shed tears to have the asthmatic patient of allergic rhinitis to fall ill.Due to the diseases associated with inflammation that asthma is a kind of irritated feature, so diagnosis often takes some irritated markup means to check.One of wherein main method is nitric oxide labelling method.This kind of gas produces from the tissue of inflammation.In the lung having inflammation, nitric oxide can be discharged along air flue.Although nitric oxide production content can not predict the degree of inflammation of asthma exactly, early stage research is still the relation being determined itself and symptoms of asthma degree by this method.
4, criterion of therapeutical effect
" in cure the desease Standardization of diagnosis and curative effect " of implementing with reference to State Administration of Traditional Chinese Medicine 1994 drafts as follows:
Clinical recovery: tcm clinical practice symptom, sign disappear or substantially disappear;
Effective: tcm clinical practice symptom, sign obviously change;
Effective: tcm clinical practice symptom, sign all take a favorable turn;
Invalid: tcm clinical practice symptom, sign are all not improved;
5, therapeutic outcome
| Group | Treatment number | Cure | Effective | Effectively | Invalid | Total effective rate |
| Allergic rhinitis | 100 | 69 | 20 | 10 | 1 | 99％ |
| Allergic pharyngitis | 100 | 75 | 20 | 5 | 0 | 100％ |
| Allergic asthma | 100 | 68 | 20 | 11 | 1 | 99％ |
6, conclusion
Teabag of the present invention has the anti-allergic effects of aobvious person, and wherein treatment of allergic rhinitis total effective rate is 99%, and treatment allergic pharyngitis total effective rate is 100%, and treatment allergic asthma total effective rate is 99%.
Experimental example three: model case
Case 1: Lee so-and-so, man, 50 years old.Symptom: the irritated body of patient is a lot, such as dust, flowers and plants.Asthma is serious, be allergic asthma through local hospital inspection, after local hospital treats two weeks, DeGrain, drink teabag of the present invention upon somebody's introduction (to prepare according to embodiment 1 method, after once-a-day) one week, asthma is clearly better, and to continue to strengthen after drinking one week asthma and entirely heals.Follow up a case by regular visits to and do not recur for 1 year.
Case 2: Zhang, female, 45 years old.Symptom: suffer from symptoms such as just going out front dry pharynx, itching throat, throat are scorching hot, hypodynia, pharyngeal blocking sense, feeling of distension and oppression before first quarter moon, be allergic pharyngitis through local hospital inspection, after local hospital treats two weeks, DeGrain, takes capsule of the present invention upon somebody's introduction and (prepares according to embodiment 2 method, a twice-daily, each two) after one week, pharyngitis symptom is clearly better, continue to strengthen to take after one week pharyngitis symptom completely without, treatment is healed entirely.Follow up a case by regular visits to and do not recur for 1 year.
Case 3: Zhao so-and-so, female, 55 years old.Symptom: the normal sneeze of patient, rhinorrhea, nose is itched, having allergies, is allergic rhinitis, on inspection after local hospital treats one week, DeGrain, take upon somebody's introduction Tablets (according to the preparation of embodiment 3 method, a twice-daily, one time two) after one week, Rhinitis Symptoms is clearly better, and continues to strengthen and takes complete after one week healing.Follow up a case by regular visits to and do not recur for 1 year.
Following embodiment all can realize the effect of above-mentioned experimental example.
Detailed description of the invention
embodiment 1 teabag
Tremella 5kg Radix Platycodonis 1.5kg Rhizoma Phragmitis 2kg
Semen Armeniacae Amarum 2kg Fructus Hippophae 0.5kg Citrus aurantium L. var. amara Engl. 0.2kg
Flos Chrysanthemi 1kg Jasmine tea 13kg.
Above-mentioned raw materials medicine is cleaned respectively, dried, wears into fine powder and cross 80 mesh sieves, by all crude drug fine powder mix homogeneously, subpackage makes teabag, makes 12600 bags.Every bag of 2g, once-a-day, each 1 bag, boiled water brews.
embodiment 2 capsule
Tremella 3kg Radix Platycodonis 2.3kg Rhizoma Phragmitis 1kg
Semen pruni armeniacae 3kg Fructus Hippophae 0.2kg Citrus aurantium L. var. amara Engl. 0.3kg
Flos Chrysanthemi 0.5kg green tea 20kg.
Said medicine conveniently technique adds customary adjuvant and makes capsule.This customary adjuvant comprises but is not defined as starch, sodium benzoate etc.; This common process comprises the former powder of medicine or part water extraction or whole water extractions.The active ingredient of crude drug and the ratio of adjuvant are 1:2, can be made into 45450 capsules, 0.4g/ grain, a twice-daily, each 2.
embodiment 3 tablet
Tremella 9kg Radix Platycodonis 0.7kg Rhizoma Phragmitis 3.8kg
Semen Armeniacae Amarum 1kg Fructus Hippophae 0.8kg Citrus aurantium L. var. amara Engl. 0.1kg
Flos Chrysanthemi 1.8kg Jasmine tea 8kg.
Said medicine conveniently technique adds customary adjuvant and makes tablet.The active ingredient of crude drug and the ratio of adjuvant are 1:1, can be made into 50400,0.2g/ sheet, a twice-daily, each 2.
embodiment 4 pill
Tremella 5kg Radix Platycodonis 1.5kg Rhizoma Phragmitis 2kg
Semen pruni armeniacae 2kg Fructus Hippophae 0.5kg Citrus aurantium L. var. amara Engl. 0.2kg
Flos Chrysanthemi 1kg Jasmine tea 13kg.
Said medicine conveniently technique adds customary adjuvant and makes honeyed pill.Above principal agent dosage makes 12600 honeyed pill, every twice-daily, each 1.
embodiment 5 granule
Tremella 4kg Radix Platycodonis 1.8kg Rhizoma Phragmitis 1.2kg
Semen Armeniacae Amarum 2.8kg Fructus Hippophae 0.4kg Citrus aurantium L. var. amara Engl. 0.28kg
Flos Chrysanthemi 0.7kg Jasmine tea 15kg.
Said medicine conveniently technique adds customary adjuvant and makes granule.Above principal agent dosage makes 12600 bags, every twice-daily, each 1 bag.
embodiment 6 oral liquid
Tremella 6kg Radix Platycodonis 1.2kg Rhizoma Phragmitis 2.8kg
Semen pruni armeniacae 1.2kg Fructus Hippophae 0.6kg Citrus aurantium L. var. amara Engl. 0.15kg
Flos Chrysanthemi 1.3kg green tea 11kg.
Said medicine is according to the common process of oral liquid, and with water extraction, oral liquid made by customary adjuvant such as sodium carboxymethyl cellulose, correctives, antiseptic etc. that extract adds convention amount.Above principal agent dosage makes 12600 oral liquids, every twice-daily, each 1.
Claims (10)
1. have a pharmaceutical composition for anti-allergic effects, it is characterized in that, the crude drug of said composition consists of:
Tremella 2-10 weight portion Radix Platycodonis 0.5-2.5 weight portion Rhizoma Phragmitis 0.5-4 weight portion
Semen Armeniacae Amarum 0.5-4 weight portion Fructus Hippophae 0.1-1 weight portion Citrus aurantium L. var. amara Engl. 0.05-0.4 weight portion
Flos Chrysanthemi 0.3-2 weight portion Folium Camelliae sinensis 5-25 weight portion.
2. compositions as claimed in claim 1, is characterized in that the crude drug of said composition consists of:
Tremella 3-7 weight portion Radix Platycodonis 1-2 weight portion Rhizoma Phragmitis 1-3 weight portion
Semen Armeniacae Amarum 1-3 weight portion Fructus Hippophae 0.3-0.7 weight portion Citrus aurantium L. var. amara Engl. 0.1-0.3 weight portion
Flos Chrysanthemi 0.5-1.5 weight portion Folium Camelliae sinensis 10-16 weight portion.
3. compositions as claimed in claim 1 or 2, is characterized in that the crude drug of said composition consists of:
Tremella 5 weight portion Radix Platycodonis 1.5 weight portion Rhizoma Phragmitis 2 weight portion
Semen Armeniacae Amarum 2 weight portion Fructus Hippophae 0.5 weight portion Citrus aurantium L. var. amara Engl. 0.2 weight portion
Flos Chrysanthemi 1 weight portion Folium Camelliae sinensis 13 weight portion.
4. compositions as claimed in claim 1 or 2, is characterized in that the crude drug of said composition consists of:
Tremella 3 weight portion Radix Platycodonis 2.3 weight portion Rhizoma Phragmitis 1 weight portion
Semen Armeniacae Amarum 3 weight portion Fructus Hippophae 0.2 weight portion Citrus aurantium L. var. amara Engl. 0.3 weight portion
Flos Chrysanthemi 0.5 weight portion Folium Camelliae sinensis 20 weight portion;
Or
Tremella 9 weight portion Radix Platycodonis 0.7 weight portion Rhizoma Phragmitis 3.8 weight portion
Semen Armeniacae Amarum 1 weight portion Fructus Hippophae 0.8 weight portion Citrus aurantium L. var. amara Engl. 0.1 weight portion
Flos Chrysanthemi 1.8 weight portion Folium Camelliae sinensis 8 weight portion.
5. the compositions as described in one of claim 1-4, is characterized in that described Semen Armeniacae Amarum is Semen Armeniacae Amarum or Semen pruni armeniacae; Described Flos Chrysanthemi is Flos Chrysanthemi; Described Folium Camelliae sinensis is green tea or Jasmine tea.
6. the compositions as described in one of claim 1-5, is characterized in that said composition is teabag, capsule, tablet, pill, granule or oral liquid.
7. the preparation method of the compositions that one of claim 1-5 is described, is characterized in that the method is: described crude drug is cleaned respectively, dried, wears into fine powder, by all crude drug fine powder mix homogeneously.
8. the preparation method of compositions as claimed in claim 7, it is characterized in that the said composition that obtains conveniently technique add customary adjuvant and make the teabag of clinical acceptance, capsule, tablet, pill, granule or oral liquid.
9. the compositions as described in one of claim 1-6 is preparing the application had in antianaphylactic medicine.
10. the application of the compositions as described in one of claim 1-6 in the medicine of preparation treatment allergic pharyngitis, allergic rhinitis and allergic asthma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510324620.5A CN104906418B (en) | 2015-06-12 | 2015-06-12 | A kind of pharmaceutical composition with anti-allergic effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510324620.5A CN104906418B (en) | 2015-06-12 | 2015-06-12 | A kind of pharmaceutical composition with anti-allergic effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104906418A true CN104906418A (en) | 2015-09-16 |
| CN104906418B CN104906418B (en) | 2016-08-31 |
Family
ID=54076134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510324620.5A Active CN104906418B (en) | 2015-06-12 | 2015-06-12 | A kind of pharmaceutical composition with anti-allergic effects |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104906418B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520529A (en) * | 2013-09-29 | 2014-01-22 | 天圣制药集团股份有限公司 | Composition for preventing or treating diseases caused by exogenous wind heat and preparation method |
-
2015
- 2015-06-12 CN CN201510324620.5A patent/CN104906418B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520529A (en) * | 2013-09-29 | 2014-01-22 | 天圣制药集团股份有限公司 | Composition for preventing or treating diseases caused by exogenous wind heat and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 吕群: "桑菊饮可治过敏性鼻炎", 《实用中西医结合杂志》 * |
| 王炎，等: "过敏性鼻炎的辨证论治", 《现代中医药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104906418B (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101385848B (en) | Medicine for treating bronchitis | |
| CN102813904B (en) | Compound medicine for treating anaphylactic rhinitis-asthma syndrome and preparation method and application thereof | |
| CN103099948A (en) | Pharmaceutical composition for treating pharyngitis and preparation method | |
| CN102526546A (en) | Chinese medicinal composition and preparation and preparation method thereof | |
| CN101850084A (en) | Chinese medicinal composition for treating tuberculosis and method for preparing same | |
| CN103041151A (en) | Traditional Chinese medicine composition for curing trachitis and preparation method thereof | |
| CN106539908A (en) | A kind of Chinese medicine composition for treating allergic rhinitises and skin allergy | |
| CN104906418B (en) | A kind of pharmaceutical composition with anti-allergic effects | |
| CN104840737B (en) | Chinese medicine composition with qi invigorating and lung moistening effect and its preparation method and application | |
| WO2021179881A1 (en) | Application of herbal medicine composition in preparation of medicine for preventing and treating coronavirus complicated with lung injury | |
| CN102698134B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method and application thereof | |
| CN102580037B (en) | Chinese medicinal composition for treating cough caused by cold-type infection and preparation method thereof | |
| CN1830482B (en) | Chinese medicinal composition and application for treating child pneumonia for treating | |
| CN104523911A (en) | Medicine for treating acute and chronic rhinitis | |
| CN104338040A (en) | Traditional Chinese medicine for treating chronic pneumonia | |
| CN102940697B (en) | Medicine for treating allergic rhinitis and bronchial asthma | |
| CN103006780A (en) | Traditional Chinese medicinal composition for treating allergic rhinitis and method for preparing same | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN102813794B (en) | Compound traditional Chinese medicine combination for treating bronchial asthma and preparation method and application thereof | |
| CN106138687A (en) | A kind of Chinese medicine composition preventing and treating the kidney deficiency type asthma | |
| CN106138675B (en) | A kind of condensed pill and preparation method thereof for treating chronic pharyngitis | |
| CN105250700A (en) | Traditional Chinese medicine for treating chronic obstructive emphysema and preparation method thereof | |
| CN104055886A (en) | Medicinal composition for treating chronic cough, and preparation method and application thereof | |
| CN104398711A (en) | Traditional Chinese medicinal composition for treating child allergic rhinitis, and preparation method and application thereof | |
| CN104666811A (en) | Preparation method of pepsin treated APR (Anemarrhena, Phellodendrom and Rehmannia) oral liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190409 Address after: 100068 Beijing Fengtai District Caoqiao Xinyuan 3 District 1 Building 6 Unit 13 1 Patentee after: Peng Gao Address before: 100037 No. 34 Zengguang Road, Haidian District, Beijing, 8-storey 807 Patentee before: BEIJING KANGZHOURUNFA HIGH-TECH CO., LTD. |
|
| TR01 | Transfer of patent right |